EMRA Rep to ACGME Review Committee for Emergency Medicine Nomination Form

Selection Timeline

EMRA Nominee Submission Deadline: September 16
Two EMRA-Endorsed Candidates Selected by September 25
ACGME will notify the selected individual in February, 2023
The new resident member’s term will begin July 1, 2027, and ending June 30, 2029.
March 2027 - June 30, 2027 New RC-EM rep will shadow current RC-EM Rep

Each submitted nomination must include:

1. Two letters of recommendation
     a. Letter of support from the nominee’s program director. This letter must include an attestation that he or she will ensure that the resident will have sufficient time to participate in activities of the Review Committee and the ACGME as required.
     b. Letter of endorsement from a professional medical society of membership or other person/group - EMRA will supply this for the nominees.
2. Resident CV
3. Completed Nomination Form (Download below)

Resident-Nominee-Form-2022.docdoc 64 KB

Application Submissions are currently closed.

Related Content

Mar 23, 2025

Severe Finger Entrapment in Gas Filler Cap Valve of 2003 Ford Expedition

How do you manage a case of a patient's finger stuck so completely in a Ford Explorer gas valve that EMS arrives with part of the vehicle attached to your patient? Hint: Consider the use of a nasopharyngeal tube, an angle grinder, and DoorDash.

Nov 02, 2022

Critical Care Alert: A Randomized Trial of Drug Route in Out-of-Hospital Cardiac Arrest

Every minute counts for long-term outcomes in out-of-hospital cardiac arrest. Does the route of administration for lifesaving medications play a role? This EMRA Critical Care Alert dives into the PARAMEDIC-3 trial, comparing outcomes in OHCA patients who were treated with intraosseous access versus intravenous access.

Dec 09, 2025

Pseudo-Subarachnoid Hemorrhage Following Cervical Medial Branch Block Using Gadolinium-Based Contrast: A Case Report and Review of the Literature

This case report explores the evidence behind recognizing and treating conditions caused by gadolinium-based contrast agents — including pseudo-subarachnoid hemorrhage.